Biotin market in March displayed a cautious tone, with prices easing and a weekly decline of 1.67% as spot availability remained adequate and trading centered on routine volumes. Early March saw a brief tightening of spot liquidity, but by the week ending 2026-03-29 sellers faced softer momentum. The market remained import-heavy, with limited upside from downstream demand, keeping quotations sideways rather than generating sustained gains. Demand support came most clearly from the feed supplement segment, while pharmaceutical and nutraceutical buyers contributed sporadic activity. ChemAnalyst indicates domestic production covers about 15% of demand while imports account for roughly 85%, underscoring import reliance. Across mid-March, liquidity tightened modestly and then normalized as Chinese cargoes moved through West Coast warehouses. No major upstream disruptions or freight bottlenecks were reported, and energy or feedstock costs were not active price drivers. Looking ahead, prices are expected to hold steady, with the import pipeline and trade flows shaping the path; surge in tenders could alter momentum.
USA Biotin prices eased in late March 2026, with a weekly decline of 1.67% as spot availability remained broadly adequate and trading was dominated by routine volumes. Opening the month, mid-March tightened spot liquidity briefly, but by the week ending 2026-03-29 sellers faced softer momentum. Overall market conditions through March were shaped by an import-heavy Biotin supply profile and muted demand signals that kept quotations on a largely sideways trajectory rather than sparking sustained Biotin price gains.
Early in the month feed supplement formulators provided the clearest Biotin demand support, but even that sector only imparted intermittent strength. As per ChemAnalyst data, domestic producers supply about 10-15% of US requirements while imports account majority, so the market remains heavily reliant on inbound cargoes. The week ending 2026-03-13 saw routine ordering tighten spot liquidity and allow sellers to secure modest premiums, while the week ending 2026-03-20 recorded balanced conditions as Chinese Biotin cargoes worked through West Coast warehouses. In contrast to feed supplements, other end-use segments such as pharmaceutical and nutraceutical buyers were not prominent in the market notes, suggesting limited incremental appetite from those channels during March.
Supply dynamics reflected the import-centric structure of the market and an absence of major upstream disruptions. The import pipeline kept Biotin spot availability adequate, while no plant outages or freight congestion were reported in the period under review. Biotin inventory rhythms tightened briefly mid-month, which supported a short-lived bullish tack, but logistical normalization and cargoes still clearing terminals eased pressure later in March. Rising energy or feedstock cost drivers were not cited as active pressures in the notes, leaving Biotin transactional liquidity and trade flows as the principal levers for pricing.
Weekly movements for Biotin displayed a choppy but contained pattern per weekly assessment data: prices fell early in March, were flat the following week, then climbed through the weeks ending 2026-03-13 and 2026-03-20 (+1.13% and +0.67% respectively) before turning lower in the week ending 2026-03-29 (-1.67%). Rather than a clear directional trend, the month featured short sequences of tightening and easing liquidity that left quotations oscillating within a relatively narrow band. The late-March drop consolidated those intra-month swings and pulled the short-term trajectory into mild weakness.
Looking ahead, our analysts expect Biotin prices to hold broadly steady in the immediate term, driven by a balanced import pipeline, routine trading volumes and the absence of reported outages. The near-term outlook is described as stable for the coming week after 2026-03-20, although any unexpected shifts in import arrival patterns or an uptick in Biotin demand from larger pharmaceutical or nutraceutical tenders could alter momentum. Forecasts are, as always, subject to market conditions and the timing of cargo clearances and ordering behaviour by key Biotin buyers.
